A multi-institution phase II study of docetaxel and S-1 in combination with trastuzumab for HER2-positive advanced gastric cancer (DASH study)
Cancer Chemotherapy and Pharmacology Jan 06, 2018
Kagawa S, et al. - This study was designed to ascertain the safety and efficacy of trastuzumab in combination with docetaxel and S-1 for human epidermal growth factor receptor 2 (HER2)-positive advanced gastric cancer (GC). Based on the findings, for patients with HER2-positive GC, trastuzumab in combination with docetaxel and S-1 had effective antitumor activity and manageable toxicities as first-line treatment.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
